MORAb 022

Drug Profile

MORAb 022

Alternative Names: MORAb-022

Latest Information Update: 06 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Morphotek
  • Developer Ludwig Institute for Cancer Research; Morphotek
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis
  • Preclinical Cancer

Most Recent Events

  • 06 Sep 2016 MORAb 022 is still in preclinical trials for Cancer in the US (Morphotek pipeline; September 2016)
  • 07 Dec 2015 Efficacy, adverse events and pharmacokinetics data from a phase-I trial in Rheumatoid arthritis released by Morphotek (NCT01357759)
  • 07 Dec 2015 Morphotek plans a phase-II trial for Rheumatoid arthritis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top